- Home
- OCTO vs TOVX Comparison
OCTO vs TOVX Comparison
Compare OCTO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCTO
- TOVX
- Stock Information
- Founded
- OCTO 1966
- TOVX 2001
- Country
- OCTO United States
- TOVX United States
- Employees
- OCTO N/A
- TOVX N/A
- Industry
- OCTO
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- OCTO
- TOVX Health Care
- Exchange
- OCTO Nasdaq
- TOVX Nasdaq
- Market Cap
- OCTO 4.2M
- TOVX 3.8M
- IPO Year
- OCTO N/A
- TOVX 2006
- Fundamental
- Price
- OCTO $1.36
- TOVX $0.49
- Analyst Decision
- OCTO
- TOVX Hold
- Analyst Count
- OCTO 0
- TOVX 1
- Target Price
- OCTO N/A
- TOVX N/A
- AVG Volume (30 Days)
- OCTO 46.3K
- TOVX 2.9M
- Earning Date
- OCTO 05-16-2025
- TOVX 05-14-2025
- Dividend Yield
- OCTO N/A
- TOVX N/A
- EPS Growth
- OCTO N/A
- TOVX N/A
- EPS
- OCTO N/A
- TOVX N/A
- Revenue
- OCTO $41,576,562.00
- TOVX N/A
- Revenue This Year
- OCTO N/A
- TOVX N/A
- Revenue Next Year
- OCTO N/A
- TOVX N/A
- P/E Ratio
- OCTO N/A
- TOVX N/A
- Revenue Growth
- OCTO N/A
- TOVX N/A
- 52 Week Low
- OCTO $0.98
- TOVX $0.40
- 52 Week High
- OCTO $4.86
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- OCTO 54.92
- TOVX 29.93
- Support Level
- OCTO $1.21
- TOVX $0.40
- Resistance Level
- OCTO $1.40
- TOVX $0.57
- Average True Range (ATR)
- OCTO 0.11
- TOVX 0.05
- MACD
- OCTO -0.01
- TOVX 0.01
- Stochastic Oscillator
- OCTO 43.94
- TOVX 40.27
About OCTO Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.